Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.53 |
| ▸ | ABL1 | P00519 | 10/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537041 | 1.00 | LRRK2 (0.53) | LRRK2ABL1CDK2CDK4KIT | |
| SCHEMBL24286637 | 0.91 | LRRK2 (0.65) | LRRK2ABL1CDK2CDK4KIT | |
| SCHEMBL29537111 | 0.91 | LRRK2 (0.65) | LRRK2ABL1CDK2CDK4KIT | |
| SCHEMBL24285954 | 0.91 | LRRK2 (0.65) | LRRK2ABL1CDK2CDK4KIT | |
| SCHEMBL29538250 | 0.91 | LRRK2 (0.65) | LRRK2ABL1CDK2CDK4KIT | |
| SCHEMBL24286023 | 0.87 | LRRK2 (0.56) | LRRK2ABL1 | |
| SCHEMBL24286228 | 0.86 | LRRK2 (0.47) | LRRK2ABL1CDK2 | |
| SCHEMBL24286639 | 0.82 | LRRK2 (0.64) | LRRK2ABL1CDK2CDK4 | |
| SCHEMBL24286613 | 0.82 | LRRK2 (0.64) | LRRK2ABL1CDK2CDK4 | |
| SCHEMBL24285958 | 0.82 | LRRK2 (0.64) | LRRK2ABL1CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214207-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1st Biotherapeutics, Inc. (KR) | 2023-07-26 | — | — | EP | claimed |
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | NLRP3, NLRP1, KCNJ2 | LRRK2 538/4885ABL1 966/4885CDK2 952/4885 |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | LRRK2 538/4885ABL1 966/4885CDK2 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.